tradingkey.logo

Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202

ReutersJul 2, 2025 12:14 PM

- Vyne Therapeutics Inc VYNE.O:

  • VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202

  • VYNE THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD FOR FEMALE PATIENTS ON 0.25 MG AND 0.5 MG DOSES

  • VYNE THERAPEUTICS INC - 12-WEEK TOXICOLOGY STUDY IN DOGS REQUIRED TO RESUME TRIAL IN MALES

  • VYNE THERAPEUTICS INC - TO STOP ENROLLING PATIENTS IN PHASE 1B PSORIASIS STUDY

  • VYNE THERAPEUTICS INC - UNBLINDS CLINICAL DATA FROM ENROLLED SUBJECTS IN STUDY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI